PYPD Stock Overview
A clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
PolyPid Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.02 |
| 52 Week High | US$9.20 |
| 52 Week Low | US$2.90 |
| Beta | 1.33 |
| 11 Month Change | -11.70% |
| 3 Month Change | -12.21% |
| 1 Year Change | -35.74% |
| 33 Year Change | -98.54% |
| 5 Year Change | n/a |
| Change since IPO | -99.47% |
Recent News & Updates
Recent updates
PolyPid set to cut 20% jobs
Oct 20PolyPid's surgical site infections treatment eligible for marketing nod submission in EU
Sep 28PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections
Sep 02PolyPid GAAP EPS of -$1.23 misses by $0.60
Aug 10PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe
Aug 03PolyPid: Strong Pipeline, Close Catalysts
Apr 19Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?
Mar 18
Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Nov 08We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth
Jul 15Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Mar 09PolyPid's oncoplex cancer program shows encouraging action in animal study
Dec 22PolyPid launches second late-stage trial with D-PLEX100 in surgical infections
Dec 16PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections
Nov 24Shareholder Returns
| PYPD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -9.6% | 0.8% | 1.0% |
| 1Y | -35.7% | 13.4% | 32.3% |
Return vs Industry: PYPD underperformed the US Pharmaceuticals industry which returned 14% over the past year.
Return vs Market: PYPD underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| PYPD volatility | |
|---|---|
| PYPD Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PYPD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PYPD's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 61 | Dikla Czaczkes Akselbrad | www.polypid.com |
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer.
PolyPid Ltd. Fundamentals Summary
| PYPD fundamental statistics | |
|---|---|
| Market cap | US$20.07m |
| Earnings (TTM) | -US$26.86m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs PYPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PYPD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$26.86m |
| Earnings | -US$26.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.95 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 357.1% |
How did PYPD perform over the long term?
See historical performance and comparison